about
Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyPrimary Retroperitoneal Cystoadenocarcinoma: A Systematic Review.The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report.Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trDose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.Systemic adjuvant therapies in renal cell carcinomaMetabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.AR-V7 and prostate cancer: The watershed for treatment selection?Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.When a thymic carcinoma "becomes" a GIST.Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer.Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma."Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.Very late recurrence of an apparently benign pheochromocytoma.Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma.
P50
Q28079861-57CBB549-B2B1-4645-9A69-0FA495B49091Q30249573-506FF7F7-A10D-4BE6-B460-F70168107194Q30250343-61FB99CB-3E2A-45DD-B4A4-984D2BF325E0Q33374065-CB02BD62-952A-4DB3-A848-7C5A278BC3BFQ33388484-D2620DE0-7431-4209-8210-EE33A90A3433Q33391020-53E1CDFB-F7FA-4D7D-8211-88EA3C81BEDAQ33417698-5AD64E8D-B250-4E31-9064-68A3DC81A1FDQ34774866-23CA1B9F-0845-4A25-AF8E-AD0417BF3F4DQ35569322-A727E30D-4569-40F2-9029-12F59B46C433Q36103157-FA76990C-576E-4882-A850-1343420D8E5DQ36291489-64771FFB-10D8-4425-B382-2A01920C1A71Q36636651-D5BFAF52-8439-49E6-8321-6B8CEB9AAFAFQ37362945-F79D3C37-4901-49FC-9DB9-066A76BA7876Q37642460-84F6DC38-785D-4D31-9174-C4D3B550709CQ38312045-3CAFB288-17D3-4A5F-A8C4-A832146C5F59Q38693856-6E7F31E7-2854-410F-824F-CDBF26732607Q38717038-F6B3E557-91AC-4F08-8323-378410642972Q38742992-AE593AFA-344D-4857-BC17-F3556FCA2046Q39009124-0FB13AA5-5EE6-46CA-8088-B5B12DA4F8AEQ39030381-184B6423-5B41-4388-8FD0-F2FFBD0497FDQ39442851-1F3F5B48-5EE6-4D68-9689-3B4CAAC5B742Q40170755-4CA214E3-0331-4E1F-A704-0CD0F7742ED7Q41078090-D28EA961-B208-4A2A-A8C7-9EEDA5C65956Q41376026-08C5AA29-ACDF-4044-8C85-910EBCD4C9CDQ41624982-9C601AE3-4B81-440B-A43C-E46444D3F25CQ41729849-5AB118C3-2367-45DD-91D1-378F571B0AC3Q42257155-E45D273E-C469-430F-89FC-68DCBDC03CB6Q46052437-DD646DD1-85A6-4010-87DF-DC325F9F0BF0Q46060710-939593DE-4D75-4BF4-BA6A-ACD27B3BD082Q47136435-75D30E66-88C5-4538-9922-75B0EAFC3660Q47151381-E9263E9C-09BA-4146-9345-A222A6F9DCADQ47261072-CE75D8BE-F40D-4FB2-9529-FB3EFAB03FC9Q47874565-3EDA76C4-C1F1-4471-816C-C36E1EC10B54Q47971266-EF2CE0F4-043A-4FFD-845E-EFBADFD3B930Q48085625-058CE98B-CEAA-4870-9A90-6A42420AC1C8Q48646811-D3E9C068-F377-4D2F-A5A5-99FAF58DCF13Q48771536-35E8D545-9008-46AE-BED4-FC27D833BE82Q51612923-97B9ACB7-0168-40D2-83AA-FF130DA893EAQ53173730-FE53AC00-9BC2-47C3-96F0-2445EB7F1FDCQ53174586-E64BB249-F00A-4992-9DCA-2A375C07D3C5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sebastiano Buti
@ast
Sebastiano Buti
@en
Sebastiano Buti
@es
Sebastiano Buti
@nl
Sebastiano Buti
@sl
type
label
Sebastiano Buti
@ast
Sebastiano Buti
@en
Sebastiano Buti
@es
Sebastiano Buti
@nl
Sebastiano Buti
@sl
prefLabel
Sebastiano Buti
@ast
Sebastiano Buti
@en
Sebastiano Buti
@es
Sebastiano Buti
@nl
Sebastiano Buti
@sl
P1053
S-1314-2017
P106
P1153
55883521400
P21
P31
P3829
P3835
sebastiano-buti
P496
0000-0003-0876-0226